Back to Search Start Over

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.

Authors :
Fu, Mingpeng
He, Qi
Guo, Zilong
Zhou, Xiaoran
Li, Heli
Zhao, Liang
Tang, Hongling
Zhou, Xiaoqi
Zhu, Huifen
Shen, Guanxin
He, Yong
Lei, Ping
Source :
Frontiers in Immunology; 6/21/2019, pN.PAG-N.PAG, 12p
Publication Year :
2019

Abstract

Bispecific T-cell engager antibodies (BiTE) have been explored as a means to recruit cytolytic T cells to kill tumor cells. The transferrin receptor (TfR) is highly expressed on the surface of rapidly proliferating tumor cells. Therefore, it holds great potential in T cell redirecting therapies. In this research, we developed a BiTE targeting TfR and CD3 (TfR-BiTE) and studied its therapeutic impact on TfR-positive cancer. TfR-BiTE had the ability to induce the selective lysis of various TfR-positive cancer cells through the activation of T cells, the release of cytokines, and then the coming proliferation of T cells, whereas TfR-negative cells were not affected. In a subcutaneous HepG2 xenograft model, low concentrations of TfR-BiTE inhibited tumor growth. Overall, these results reveal that TfR-BiTE can selectively deplete TfR-positive HepG2 cells; hence, it represents a novel immunotherapeutic approach for the treatment of hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16643224
Database :
Complementary Index
Journal :
Frontiers in Immunology
Publication Type :
Academic Journal
Accession number :
137117279
Full Text :
https://doi.org/10.3389/fimmu.2019.01396